OTC Markets OTCPK - Delayed Quote USD

Oxford Nanopore Technologies plc (ONTTF)

Compare
1.3500
-0.1700
(-11.18%)
As of 12:03:27 PM EST. Market Open.
Currency in GBP All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
169,668
169,668
198,603
133,661
113,860
Cost of Revenue
79,187
79,187
74,793
60,466
66,981
Gross Profit
90,481
90,481
123,810
73,195
46,879
Operating Expense
259,090
259,090
222,289
237,728
119,939
Operating Income
-168,609
-168,609
-98,479
-164,533
-73,060
Net Non Operating Interest Income Expense
16,647
16,647
4,313
-684
-656
Pretax Income
-149,768
-149,768
-83,411
-166,004
-73,153
Tax Provision
4,739
4,739
7,614
1,609
-11,909
Net Income Common Stockholders
-154,507
-154,507
-91,025
-167,613
-61,244
Diluted NI Available to Com Stockholders
-154,507
-154,507
-91,025
-167,613
-61,244
Basic EPS
-0.19
-0.19
-0.11
-0.23
-0.08
Diluted EPS
-0.19
-0.19
-0.11
-0.23
-0.08
Basic Average Shares
833,960.3580
833,960.3580
823,742.7090
731,938.5860
794,668.8600
Diluted Average Shares
833,960.3580
833,960.3580
823,742.7090
731,938.5860
794,668.8600
Total Operating Income as Reported
-168,609
-168,609
-98,479
-164,533
-73,060
Rent Expense Supplemental
928
928
602
180
82
Total Expenses
338,277
338,277
297,082
298,194
186,920
Net Income from Continuing & Discontinued Operation
-154,507
-154,507
-91,025
-167,613
-61,244
Normalized Income
-156,468.8200
-156,468.8200
-99,929.3300
-167,027.3700
-61,716.2444
Interest Income
18,853
18,853
5,941
224
91
Interest Expense
2,206
2,206
1,628
908
747
Net Interest Income
16,647
16,647
4,313
-684
-656
EBIT
-147,562
-147,562
-81,783
-165,096
-72,406
EBITDA
-105,935
-105,935
-49,912
-140,405
-55,071
Reconciled Cost of Revenue
79,187
79,187
74,793
60,466
66,981
Reconciled Depreciation
41,627
41,627
31,871
24,691
17,335
Net Income from Continuing Operation Net Minority Interest
-154,507
-154,507
-91,025
-167,613
-61,244
Total Unusual Items Excluding Goodwill
2,422
2,422
10,993
-723
563
Total Unusual Items
2,422
2,422
10,993
-723
563
Normalized EBITDA
-108,357
-108,357
-60,905
-139,682
-55,634
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0002
0.0002
Tax Effect of Unusual Items
460.1800
460.1800
2,088.6700
-137.3700
90.7556
12/31/2020 - 10/15/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

1AE.F argenx SE
600.20
+1.73%
 
GNRO.PA GeNeuro SA
0.0990
0.00%
 
KRBP Kiromic BioPharma, Inc.
1.5000
0.00%
 
NWRN.SW Newron Pharmaceuticals S.p.A.
9.72
-1.82%
 
GNFT.PA Genfit S.A.
3.4850
0.00%
 
DNTH Dianthus Therapeutics, Inc.
20.05
-7.18%
 
BION.SW BB Biotech AG Ord
36.90
-0.27%
 
IVA Inventiva S.A.
3.0150
-1.79%
 
RLF.SW Relief Therapeutics Holding SA
3.0700
-2.54%
 
BVNRY Bavarian Nordic A/S
7.72
-0.64%